Literature DB >> 8994122

High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques.

I L Simone1, F Federico, M Trojano, C Tortorella, M Liguori, P Giannini, E Picciola, G Natile, P Livrea.   

Abstract

Proton magnetic spectroscopy (1H-MRS) investigation was performed on CSF samples of patients with neurological inflammatory diseases including 52 cases of multiple sclerosis (MS). 12 acute idiopathic polyneuropathies, 20 acute meningitides (10 viral and 10 bacterial). Spectra were compared with those acquired in 18 neurological controls. High CSF lactate levels were found in MS patients during clinical exacerbation of relapsing-remitting course (p = 0.036 vs neurological controls). In MS patients with MRI evidence of Gd-enhanced plaques CSF lactate was higher than in patients with MRI inactive plaques (p = 0.017). CSF lactate positivity correlated with number of CSF mononuclear cells in MS patients with clinical activity (p = 0.05) as well as in MS patients with MRI enhancement (p = 0.003). A comparative 1H-MRS investigation in vivo on localized demyelinating areas confirmed an elevated lactate signal in Gd-enhanced (61%) more frequently than in unenhanced (22%) plaques (p = 0.03). MS patients with high lactate signal in active plaques showed high lactate levels in CSF. Increased CSF lactate was found also in patients with acute meningitis and idiopathic polyneuropathy. These data suggest that changes in lactate levels may depend on anaerobic glycolytic metabolism in activated leukocytes during inflammatory diseases. A decrease of CSF formulate levels was found in MS patients during active and inactive clinical phase (p = 0.037, p=0.05 vs neurological controls respectively). Formate changes might be related to a disorder of choline-glycine cycle in MS. 1H-MRS in vivo showed significant increase of choline in acute plaques, whereas a decrease of N-acetyl aspartate was found in chronic plaques; these metabolites are undetectable in CSF. CSF glucose levels were lower in bacterial than in viral meningitis (p = 0.014) and in neurological controls (p = 0.05). These observations suggest that 1H-MRS may be able to detect CSF metabolic impairment in neurological inflammatory diseases. In MS some CSF findings reflect metabolic changes occurring in brain demyelinating areas, and they could be useful foe evaluation of disease activity in different stages of disease evolution.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8994122     DOI: 10.1016/s0022-510x(96)00224-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  22 in total

Review 1.  Metabolomics: moving to the clinic.

Authors:  Anders Nordström; Rolf Lewensohn
Journal:  J Neuroimmune Pharmacol       Date:  2009-04-28       Impact factor: 4.147

2.  Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV.

Authors:  I L Simone; F Federico; C Tortorella; C F Andreula; G B Zimatore; P Giannini; G Angarano; V Lucivero; P Picciola; D Carrara; A Bellacosa; P Livrea
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

Review 3.  Energy failure in multiple sclerosis and its investigation using MR techniques.

Authors:  David Paling; Xavier Golay; Claudia Wheeler-Kingshott; Raju Kapoor; David Miller
Journal:  J Neurol       Date:  2011-06-10       Impact factor: 4.849

4.  Axonal damage in multiple sclerosis.

Authors:  Jeffery D Haines; Matilde Inglese; Patrizia Casaccia
Journal:  Mt Sinai J Med       Date:  2011 Mar-Apr

5.  Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.

Authors:  William T Regenold; Pornima Phatak; Michael J Makley; Roger D Stone; Mitchel A Kling
Journal:  J Neurol Sci       Date:  2008-09-09       Impact factor: 3.181

Review 6.  The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics.

Authors:  Carlos R Camara-Lemarroy; Luanne Metz; Jonathan B Meddings; Keith A Sharkey; V Wee Yong
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

7.  Hyperpolarized 13C MR metabolic imaging can detect neuroinflammation in vivo in a multiple sclerosis murine model.

Authors:  Caroline Guglielmetti; Chloé Najac; Alessandro Didonna; Annemie Van der Linden; Sabrina M Ronen; Myriam M Chaumeil
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-31       Impact factor: 11.205

Review 8.  Stem Cell Therapies for Progressive Multiple Sclerosis.

Authors:  Jayden A Smith; Alexandra M Nicaise; Rosana-Bristena Ionescu; Regan Hamel; Luca Peruzzotti-Jametti; Stefano Pluchino
Journal:  Front Cell Dev Biol       Date:  2021-07-09

9.  Multi-platform characterization of the human cerebrospinal fluid metabolome: a comprehensive and quantitative update.

Authors:  Rupasri Mandal; An Chi Guo; Kruti K Chaudhary; Philip Liu; Faizath S Yallou; Edison Dong; Farid Aziat; David S Wishart
Journal:  Genome Med       Date:  2012-04-30       Impact factor: 11.117

10.  Inflammatory multiple-sclerosis plaques generate characteristic metabolic profiles in cerebrospinal fluid.

Authors:  Norbert W Lutz; Angèle Viola; Irina Malikova; Sylviane Confort-Gouny; Bertrand Audoin; Jean-Philippe Ranjeva; Jean Pelletier; Patrick J Cozzone
Journal:  PLoS One       Date:  2007-07-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.